Cardiomyopathy, Hypertrophic

"Cardiomyopathy, Hypertrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Descriptor ID	D002312
MeSH Number(s)	C14.280.238.100 C14.280.484.150.070.160
Concept/Terms	Cardiomyopathy, Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathies, Hypertrophic Hypertrophic Cardiomyopathies Hypertrophic Cardiomyopathy Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathies, Hypertrophic Obstructive Hypertrophic Obstructive Cardiomyopathies Hypertrophic Obstructive Cardiomyopathy Obstructive Cardiomyopathies, Hypertrophic Obstructive Cardiomyopathy, Hypertrophic

Below are MeSH descriptors whose meaning is more general than "Cardiomyopathy, Hypertrophic".

Diseases [C]
Cardiovascular Diseases [C14]
Heart Diseases [C14.280]
Cardiomyopathies [C14.280.238]
Cardiomyopathy, Hypertrophic [C14.280.238.100]
Heart Valve Diseases [C14.280.484]
Aortic Valve Stenosis [C14.280.484.150]
Aortic Stenosis, Subvalvular [C14.280.484.150.070]
Cardiomyopathy, Hypertrophic [C14.280.484.150.070.160]

Below are MeSH descriptors whose meaning is related to "Cardiomyopathy, Hypertrophic".

Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathy, Hypertrophic".

Cardiomyopathy, Hypertrophic
Cardiomyopathy, Hypertrophic, Familial

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiomyopathy, Hypertrophic" by people in this website by year, and whether "Cardiomyopathy, Hypertrophic" was a major or minor topic of these publications.

Bar chart showing 24 publications over 14 distinct years, with a maximum of 3 publications in 2014 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2005	1	0	1
2010	1	0	1
2012	2	0	2
2013	2	0	2
2014	3	0	3
2015	1	1	2
2016	1	0	1
2020	1	0	1
2021	3	0	3
2022	2	0	2
2023	2	0	2
2024	1	0	1
2025	2	0	2

Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.

Papapostolou S, Iles L, O'Brien J, Gutman SJ, Ellims A, Hare J, Stub D, Moir S, Taylor AJ. The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JACC Heart Fail. 2025 Jul; 13(7):102415.

View in: PubMed
Gao YP, Liu HY, Bi XJ, Sun J, Zhu Y, Zhou W, Fan YT, Cheng XQ, Huang PN, Liu YN, Deng YB. H2FPEF and HFA-PEFF scores for heart failure risk stratification in hypertrophic cardiomyopathy patients. ESC Heart Fail. 2025 Jun; 12(3):2225-2238.

View in: PubMed
Paratz ED, Stub D, Sutherland N, Gutman S, La Gerche A, Mariani J, Taylor A, Ellims A. Response to: Regard to assessing agreement between two raters with kappa statistics. Int J Cardiol. 2024 Jun 01; 404:131978.

View in: PubMed
Paratz ED, Stub D, Sutherland N, Gutman S, La Gerche A, Mariani J, Taylor A, Ellims A. The challenge of risk stratification in hypertrophic cardiomyopathy: Clinical, genetic and imaging insights from a quaternary referral centre. Int J Cardiol. 2024 01 15; 395:131416.

View in: PubMed
Rhee TM, Kim HK, Kim BS, Han KD, Lee HJ, Hwang IC, Lee H, Park JB, Yoon YE, Kim YJ, Cho GY. Impact of coronary artery revascularization on long-term outcome in hypertrophic cardiomyopathy patients: a nationwide population-based cohort study. Sci Rep. 2023 04 19; 13(1):6412.

View in: PubMed
Choi YJ, Kim B, Rhee TM, Lee HJ, Lee H, Park JB, Lee SP, Han KD, Kim YJ, Kim HK. Augmented risk of ischemic stroke in hypertrophic cardiomyopathy patients without documented atrial fibrillation. Sci Rep. 2022 09 22; 12(1):15785.

View in: PubMed
Kwon S, Kim HK, Kim B, Lee HJ, Han KD, Hwang IC, Yoon YE, Park JB, Lee H, Lee SP, Cho GY, Kim YJ. Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy. Sci Rep. 2022 04 16; 12(1):6386.

View in: PubMed
M?ndez I, Fern?ndez AI, Espinosa M?, Cuenca S, Lorca R, Rodr?guez JF, Tamargo M, Garc?a-Montero M, G?mez C, Vilches S, V?zquez N, ?lvarez R, Medrano C, Yotti R, Fern?ndez-Avil?s F, Bermejo J. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males. Open Heart. 2021 09; 8(2).

View in: PubMed
Captur G, Manisty CH, Raman B, Marchi A, Wong TC, Ariga R, Bhuva A, Ormondroyd E, Lobascio I, Camaioni C, Loizos S, Bonsu-Ofori J, Turer A, Zaha VG, Augutsto JB, Davies RH, Taylor AJ, Nasis A, Al-Mallah MH, Valentin S, Perez de Arenaza D, Patel V, Westwood M, Petersen SE, Li C, Tang L, Nakamori S, Nezafat R, Kwong RY, Ho CY, Fraser AG, Watkins H, Elliott PM, Neubauer S, Lloyd G, Olivotto I, Nihoyannopoulos P, Moon JC. Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. JACC Cardiovasc Imaging. 2021 11; 14(11):2123-2134.

View in: PubMed
Kim M, Kim B, Choi YJ, Lee HJ, Lee H, Park JB, Lee SP, Han KD, Kim YJ, Kim HK. Sex differences in the prognosis of patients with hypertrophic cardiomyopathy. Sci Rep. 2021 03 01; 11(1):4854.

View in: PubMed

People

Explore

Similar Concepts

Top Journals